分化型甲状腺癌术后促甲状腺素抑制治疗现状

doi:10.3760/cma.j.issn.1673-422X.2014.08.009

国际肿瘤学杂志 ›› 2014, Vol. 41 ›› Issue (8): 585-587.doi: 10.3760/cma.j.issn.1673-422X.2014.08.009

分化型甲状腺癌术后促甲状腺素抑制治疗现状

侯秀秀,葛明华

325035温州医科大学第一临床学院；浙江省肿瘤医院头颈外科浙江省肿瘤研究所

收稿日期:2014-02-16 修回日期:2014-03-15 出版日期:2014-08-15 发布日期:2014-08-14
通讯作者: 葛明华，E-mail：gemingh@163.com E-mail:gemingh@163.com
基金资助:
卫生部科学研究基金-浙江省医药卫生重大科技计划（WKJ2012-2-021）；浙江省卫生高层次创新人才培养工程基金（2008-134）

Postoperation TSH suppression therapy in differentiated thyroid carcinoma

Hou Xiuxiu, Ge Minghua

First Clinical Medical College, Wenzhou Medical University, Wenzhou 325035; Department of Head and Neck Surgery, Zhejiang Province Cancer Hospital, Zhejiang Cancer Research Institute, Hangzhou 310022, China

Received:2014-02-16 Revised:2014-03-15 Online:2014-08-15 Published:2014-08-14
Contact: Ge Minghua E-mail:gemingh@163.com

摘要/Abstract

摘要： 外科手术依然是甲状腺癌尤其是分化型甲状腺癌的主要治疗手段，术后内分泌治疗被认为是重要的辅助治疗手段，其不仅可以防止术后发生甲状腺功能低下，而且能降低甲状腺癌患者术后的复发率及死亡率。

关键词: 癌, 乳头状, 甲状腺肿瘤, 治疗

Abstract: Surgical operation is still the main means of thyroid carcinoma, especially the differentiated thyroid carcinoma. Postoperative endocrine therapy is considered as an important adjuvant therapy. Giving the corresponding endocrine therapy after the surgery, not only prevent the hypothyroidism, but also reduce the recurrence rate and mortality in postoperative patients with thyroid carcinoma.

Key words: Carcinoma, papillary, Thyroid neoplasms, Therapy

侯秀秀,葛明华. 分化型甲状腺癌术后促甲状腺素抑制治疗现状[J]. 国际肿瘤学杂志, 2014, 41(8): 585-587.

Hou Xiuxiu, Ge Minghua. Postoperation TSH suppression therapy in differentiated thyroid carcinoma[J]. Journal of International Oncology, 2014, 41(8): 585-587.

参考文献

［1］ Agate L, Lorusso L, Elisei R. New and old knowledge on differentiated thyroid cancer epidemiology and risk factors［J］. J Endocrinol Invest, 2012, 35 Suppl 6:3-9. ［2］ Siegel R, Ward E, Brawley O, et al. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths［J］. CA Cancer J Clin, 2011, 61(4):212-236. ［3］ American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer［J］. Thyroid, 2009, 19(11):11671214. ［4］ Alagi′cSmailbegovi′c J, Kucukali′cSelimovi′c E, Seti′c I, et al. Importance of measurement of thyroglobulin and antithyroglobulin antibodies in differentiated thyroid cancer［J］. Coll Antropol, 2012, 36 Suppl 2:33-38. ［5］ McLeod DS, Watters KF, Carpenter AD, et al. Thyrotropin and thyroid cancer diagnosis:a systematic review and doseresponse metaanalysis［J］. J Clin Endocrinol Metab, 2012, 97(8):2682-2692. ［6］ Brabant G. Thyrotropin suppressive therapy in thyroid carcinoma:what are the targets?［J］. J Clin Endocrinol Metab, 2008, 93(4):1167-1169. ［7］ Biondi B, Cooper DS. Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer［J］. Thyroid, 2010, 20(2):135-146. ［8］ Pacini F, Castagna MG, Brilli L, et al. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and followup［J］. Ann Oncol, 2012, 23 Suppl 7:110-119. ［9］ Hovens GC, Stokkel MP, Kievit J, et al. Associations of serum thyrotropin concentrations with recurrence and death in differentiated thyroid cancer［J］. J Clin Endocrinol Metab, 2007, 92(7):2610-2615. ［10］ Biondi B, Cooper DS. The clinical significance of subclinical thyroid dysfunction［J］. Endocr Rev, 2008, 29(1):76-131. ［11］ Jonklass J, Davidson B, Bhagat S, et al. Triiodothyronine levels in athyreotic individuals during levothyroxine therapy［J］. JAMA, 2008, 299(7):769-777. ［12］ Hoang TD, Olsen CH, Mai VQ, et al. Desiccated thyroid extract compared with levothyroxine in the treatment of hypothyroidism:a randomized, doubleblind, crossover study［J］. J Clin Endocrinol Metab, 2013, 98(5):1982-1990. ［13］ Trimboli P, La Torre D, Ceriani L, et al. High sensitive thyroglobulin assay on thyroxine therapy: can it avoid stimulation test in low and high risk differentiated thyroid carcinoma patients?［J］. Horm Metab Res, 2013, 45(9):664-668. ［14］ Gharib H, Papini E, Paschke R, et al. American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association medical guidelines for clinical practice for the diagnosis and management of thyroid nodules: executive summary of recommendations［J］. J Endocrinol Invest, 2010, 33 Suppl 5:51-56. ［15］ Molinaro E, Viola D, Passannanti P, et al. Recombinant human TSH(rhTSH) in 2009:new perspectives in diagnosis and therapy［J］. Q J Nucl Med Mol Imaging, 2009, 53(5):490502. ［16］ Lee J, Yun MJ, Nam KH, et al. Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroidstimulating hormone administration for lowdose radioiodine remnant ablation of differentiated thyroid carcinoma［J］. Thyroid, 2010, 20(2):173-179. ［17］李跃松, 戴军, 陈永伟, 等. 血清TgAb的测定在分化型甲状腺癌中的作用［J］.标记免疫分析与临床, 2010, 17(5):296-298. ［18］ Spencer C, Fatemi S. Thyroglobulin antibody (TgAb) methodsStrengths, pitfalls and clinical utility for monitoring TgAbpositive patients with differentiated thyroid cancer［J］. Best Pract Res Clin Endocrinol Metab, 2013, 27(5):701-712. ［19］ Flynn RW, Bonellie SR, Jung RT, et al. Serum thyroidstimulating hormone concentration and morbidity from cardiovascular disease and fractures in patients on longterm thyroxine therapy［J］. J Clin Endocrinol Metab, 2010, 95(1):186-193.

[1]	钱晓涛, 石子宜, 胡格, 吴晓维. Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[4]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[5]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[6]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[7]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[8]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华. 炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[9]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[10]	顾芳萌, 徐晨阳, 雷大鹏. 人工智能辅助电子喉镜检查在喉癌及喉癌前病变诊治中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(5): 303-307.
[11]	王培鑫, 赵军, 徐世红, 姜朝阳, 王小强, 杨红娟. 铁死亡相关机制在骨肉瘤中的应用进展[J]. 国际肿瘤学杂志, 2024, 51(5): 308-311.
[12]	张文馨, 夏泠, 彭晋, 周福祥. 甲胎蛋白升高型胃肝样腺癌1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(5): 312-315.
[13]	王昆, 周中新, 臧其威. 血清TGF-β1、VEGF水平对非小细胞肺癌患者单孔胸腔镜根治术后复发的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 198-203.
[14]	杨毫, 施贵冬, 张程城, 张跃, 张力文, 付茂勇. 信迪利单抗与替雷利珠单抗在进展期食管鳞状细胞癌新辅助治疗中的疗效及安全性对比[J]. 国际肿瘤学杂志, 2024, 51(4): 210-216.
[15]	姚益新, 沈煜霖. 血清SOCS3、TXNIP水平对肝细胞癌TACE治疗预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 217-222.

分化型甲状腺癌术后促甲状腺素抑制治疗现状

Postoperation TSH suppression therapy in differentiated thyroid carcinoma

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价